Fresenius Kabi wins FDA approval for Dr. Reddy’s rituximab biosimilar in US
RDY•FDA approval and U.S. rights
- Fresenius Kabi secured exclusive U.S. commercialization rights for an FDA-cleared rituximab biosimilar referencing Rituxan.
- Dr. Reddy’s Laboratories developed, manufactured, and filed the biosimilar, positioning Fresenius Kabi to expand its U.S. biosimilars portfolio.
